Biofrontera Inc
About
Biofrontera Inc (NASDAQ:BFRI) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 19 2026
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Mar 9 2026
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
Mar 9 2026
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
Feb 26 2026
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
Feb 17 2026
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
Financials
Revenue
$41.7 M
Market Cap
$11.41 M
EPS
-1.04